All News

Telemedicine.MD.Computer.phone (keep)

Telehealth Diet and Exercise Benefits Knee Osteoarthritis

d Jack Cush, MD

Annals of Internal Medicine has reported the results of a randomized clinical trial showing that telehealth-delivered exercise and diet programs improved pain and function in knee osteoarthritis patients who were overweight.  While both were beneficial, exercise had a greater effect than die

Read Article
rare

Risks associated with mortality in VEXAS

d Md Yuzaiful Md Yusof, MRCP(UK), PhD

Vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic syndrome (VEXAS) took the centre stage when it was first introduced at ACR20 last year. It got everyone’s thinking that they might have encountered one or two patients in their rheumatology lifetime who might have this condition.

Read Article
FDA.Safety.jpg

FDA Puts Boxed Warnings on JAK Inhibitors

d Jack Cush, MD

Based on the safety review of tofacitinib in Pfizer's Oral Surveillance (1133) study, the FDA has added serious boxed warnings to all three marketed JAK inhibitors (for inflammatory diseases) and formalized the recommendation that patients should be started on a TNF inhibitor (TNFi) before trying a JAK inhibitor. These recommendations apply to tofacitinib, baricitinib and upadacitinib.

Read Article
JAK Safety -- The Lowdown on Infection https://t.co/Mi6EDqP7RE https://t.co/ZVZaXHGHIk

Links:

Dr. John Cush RheumNow ( View Tweet)
Rheumatology Roundup! Drs. Cush and Kavanaugh convene for their annual impromptu review of some of the best and more interesting abstracts presented at ACR 2021. https://t.co/rp7TT6nTMA https://t.co/Zk73M6OUqO

Links:

Dr. John Cush RheumNow ( View Tweet)
Closing a Chapter: Interview with Dr. David Karp, 84th ACR President 2020-2021 https://t.co/GuE9NdkHlN https://t.co/8e2cUO7Qs3

Links:

Dr. John Cush RheumNow ( View Tweet)
Tofacitinib and Malignancy Risk Dr. David Liew interviews Dr. Seoyoung Kim at the ACR21 annual meeting. https://t.co/vaoxuy6u5j https://t.co/t3kpMEqy9O

Links:

Dr. John Cush RheumNow ( View Tweet)
Spondyloarthritis Panel Discussion: ACR21 Meeting https://t.co/lR6zPHKpOo https://t.co/JGsloJUD2t

Links:

Dr. John Cush RheumNow ( View Tweet)
CDC and the ICD-10 Coordination and Maintenance Committee has assigned a diagnostic code for non-radiographic axial spondyloarthritis (nr-axSpA) == M45.A

Dr. John Cush RheumNow ( View Tweet)

TNF Inhibitor Panel Discussion: ACR21 Annual Meeting https://t.co/Kpj80YoDmN https://t.co/AChUVw17oc

Links:

Dr. John Cush RheumNow ( View Tweet)

Download Available! AOSD Disease Patterns Over Time https://t.co/qZBtCQ2QAg https://t.co/fMmN1PAzFG

Links:

Dr. John Cush RheumNow ( View Tweet)
TNF inhibitors and radiographic progression in axSpA A remaining challenge for clinicians is the ability to delay, if not completely stop, structural progression in patients with (ax-Spa, whether they are diagnosed with -axSpa or nr-axSpA disease. https://t.co/Gn9vFlq0Bd https://t.co/CXdlU0HQG8

Links:

Dr. John Cush RheumNow ( View Tweet)
ICYMI:Methotrexate and hepatic fibrosis: we must be doing something right Despite methotrexate’s use in rheumatology, and the consequent frequency of patient counselling about it, relatively little is known about what precautions are absolutely required. https://t.co/AMvnQnMUUl https://t.co/aRzsy4ZA8z

Links:

Dr. John Cush RheumNow ( View Tweet)
ICYMI: New Insights into Uveitis in Spondyloarthritis Uveitis is the most frequent extra-musculoskeletal manifestation (EAM) in Axial Spondyloarthritis (axSpA). Read more on RheumNow. https://t.co/JF7TtE8SVJ https://t.co/Sw2b1WX5ko

Links:

Dr. John Cush RheumNow ( View Tweet)
ICYMI: Diagnosing (Bad) VEXAS: The Experts Speak Dr. Cush discusses Dr. Marcela Ferrada and Dr. David Beck to discuss VEXAS syndrome and abstract 1426, which was presented at the ACR21 annual meeting. https://t.co/oafDX0rJIl https://t.co/UoNpjABLNd

Links:

Dr. John Cush RheumNow ( View Tweet)
Guselkemab vs. Ustekinumab in PsA https://t.co/JCs5VpkyUK https://t.co/OzRtdWtqXp

Links:

Dr. John Cush RheumNow ( View Tweet)
ICYMI: DORIS - Defining Remission in Lupus Proponents of treat to target in systemic lupus erythematosus (SLE) have all agreed that "remission" should be the goal, but defining remission may be tricky in SLE. Read on... https://t.co/hVfzAtRzgY https://t.co/hSPz1eASzF

Links:

Dr. John Cush RheumNow ( View Tweet)
ICYMI: Giant Cell Arteritis Novel Treatment Options https://t.co/ywqGZNmHOa https://t.co/2hLESL1RjO

Links:

Dr. John Cush RheumNow ( View Tweet)
ICYMI: IL-35 (blood and urine) is elevated in #SLE pts with nephritis. Small study of 42 SLE pts serum IL-35 had 90% sensitivity & 65% specificity while urine IL-35 had 86.4% sensitivity and 75% specificity to establish the diagnosis of LN https://t.co/SgmGDSU8dZ

Links:

Dr. John Cush RheumNow ( View Tweet)

Telemedicine Upside Interview with Dr. Alvin Wells Dr. Jack Cush interviews telemedicine guru, Dr. Alvin Wells, on the current state of telemedicine and what the future holds for telehealth in rheumatology. https://t.co/iOpKqjIVuP https://t.co/emseMx4iZ0

Links:

Dr. John Cush RheumNow ( View Tweet)
×